Midostaurin (PKC412)

Catalog No.S8064 Synonyms: CGP 41251

Midostaurin (PKC412) Chemical Structure

Molecular Weight(MW): 570.64

Midostaurin (pkc412) is a multi-targeted kinase inhibitor, including PKCα/β/γ, Syk, Flk-1, Akt, PKA, c-Kit, c-Fgr, c-Src, FLT3, PDFRβ and VEGFR1/2 with IC50 ranging from 80-500 nM.

Size Price Stock Quantity  
USD 110 In stock
USD 370 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 7 Publications

2 Customer Reviews

  • (f and g) Induction of apoptosis in HMC-1.1 and -1.2, respectively. Columns represent the mean of three independent experiments and the bars represent the standard error. ctrl, control; mido, midostaurin.

    Leukemia, 2018, 32(1):139-148. Midostaurin (PKC412) purchased from Selleck.

    PKC412 is cytotoxic to human HNSCC cells. The established HNSCC cells (SQ20B and SCC‐9 cell lines), primary human oral carcinoma cells (“Primary1/2”) and primary oral epithelial cells (“Epithelial”), were treated with indicated concentrations of PKC412. Cells were then cultured in complete medium for the applied time, and cell survival was tested by the MTT assay (a, d) and colony formation assay (c). Cell death was tested by the trypan blue staining assay (b). “CTR” indicates medium‐treated control group (for all figures). All the experiments were repeated five times, and similar results were obtained. n = 5 for each assay. Error bars indicate mean ± SD (for all figures). *p < 0.05 versus group “CTR.” HNSCC, head and neck squamous cell carcinoma; MTT, 3‐(4,5‐dimethyl‐thiazol-2-yl)2,5-diphenyl tetrazolium bromide; OD, optical density; PKC, protein kinase C

    J Cell Physiol, 2018, 233(12):9437-9446. Midostaurin (PKC412) purchased from Selleck.

Purity & Quality Control

Choose Selective PKC Inhibitors

Biological Activity

Description Midostaurin (pkc412) is a multi-targeted kinase inhibitor, including PKCα/β/γ, Syk, Flk-1, Akt, PKA, c-Kit, c-Fgr, c-Src, FLT3, PDFRβ and VEGFR1/2 with IC50 ranging from 80-500 nM.
Targets
PKCα [1]
(Cell-free assay)
PKCγ [1]
(Cell-free assay)
PKCβ1 [1]
(Cell-free assay)
PKCβ2 [1]
(Cell-free assay)
PPK [1]
(Cell-free assay)
22 nM 24 nM 30 nM 31 nM 38 nM
In vitro

Midostaurin(pkc412) is a broad spectrum protein kinase inhibitor. Midostaurin(pkc412) interacts strongly with ATP binding sites of the conventional PKC-α, -β and -γ, PDGFRβ, VEGF-R2, VEGF-R1 and the cyclin-dependant kinase 1-cyclin B complex. Midostaurin(pkc412) inhibits the growth of various human and animal cell lines in vitro at similar submicromolar concentrations. Midostaurin(pkc412) also effectively inhibits the in vitro proliferation of glioblastoma and induced the accumulation of cells in G2/M and formation of giant nuclei with extensive fragmentation and apoptotic bodies. Midostaurin(pkc412) is able to reverse the p-glycoprotein-mediated multidrug resistance of tumor cells in vitro. [1]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
human MV4-11 cells NUD0S4JWS3m2b4TvfIlkcXS7IHHzd4F6 M{i4NFczKGh? MXzDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDNWlQuOTFiY3XscJMh[W[2ZYKgO|IhcHK|IHL5JINmdGxidHn0[ZIu[my3ZTDhd5NigSxiSVO1NF0yOiCwTR?= M2LXN|E6PjV2NEC4
RS4-11 cells M3zIVGZ2dmO2aX;uJIF{e2G7 M4i2UVIhcA>? NF;MdpZKdmirYnn0bY9vKG:oIF\MWFMhUVSGIH31eIFvfCCjdYTvdIhwe3Cqb4L5cIF1cW:wIHnuJIh2dWGwIGLTOE0yOSClZXzsd{Bi\nSncjCyJIhzeyCkeTDlcIVkfHKxY3jlcYltfW2rbnXzZ4Vv[2ViYYPzZZktKEmFNUC9NVMhdk1? MoPrNVk3PTR2MEi=
CGTH-W-1 cell NX62NIJbT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NWm0d4VIUW6qaXLpeIlwdiCxZjDoeY1idiCFR2TIMXcuOSClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTR{Lk[1JO69VQ>? MlfCV2FPT0WU
SW982 cell M3PyUGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NHL2Z21KdmirYnn0bY9vKG:oIHj1cYFvKFOZOUiyJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9OFUvPThizszN NHv4VnNUSU6JRWK=
human EoL-1-cell cell M13a[Wdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MWHJcohq[mm2aX;uJI9nKGi3bXHuJGVwVC1zLXPlcIwh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF02Oi5yODDuUS=> NE\pdY1USU6JRWK=
MOLM-13 cells M17yb2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NVLoSZJQPzJiaB?= NWfGS4NMUW6qaXLpeIlwdiCxZjDGUHQ{KEmWRDDo[ZRmem:8eXfveZMhdXW2YX70JIlvKGi3bXHuJG1QVE1vMUOgZ4VtdHNiYYPz[ZN{\WRiYYOgZ4VtdCCpcn;3eIghcW6qaXLpeIlwdiCjZoTldkA4OiCqcoOgZpkhVVSVIHHzd4F6NCCJSUWwQVAvODV3IN88US=> M13jNlI3ODhzMEKz
KASUMI-1 cell M2rwV2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NGq0NZdKdmirYnn0bY9vKG:oIHj1cYFvKEuDU2XNTU0yKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OC5yNkCxOkDPxE1? M4TsTnNCVkeHUh?=
NCI-H1755 cell NFTzb4RIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MknqTY5pcWKrdHnvckBw\iCqdX3hckBPS0lvSEG3OVUh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0xNjB4MkezJO69VQ>? M3:1eXNCVkeHUh?=
human MES-SA cell MWLHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NGC4blNKdmirYnn0bY9vKG:oIHj1cYFvKE2HUz3TRUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVAvODd3NESg{txO MkK1V2FPT0WU
human HCC1395 cell NHzGSYlIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NFnrWZVKdmirYnn0bY9vKG:oIHj1cYFvKEiFQ{GzPVUh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0xNjB6NEK4JO69VQ>? M4i1W3NCVkeHUh?=
human D-336MG cell NUW2eWE4T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NYj4O4w6UW6qaXLpeIlwdiCxZjDoeY1idiCGLUOzOm1IKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OC5yOEe1OEDPxE1? NVzPVotpW0GQR1XS
CHP-212 cell MlfXS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? M2TMfGlvcGmkaYTpc44hd2ZiaIXtZY4hS0iSLUKxNkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVAvODh5N{Og{txO NVuwWYZQW0GQR1XS
human KM12 cell NHy0UolIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MWTJcohq[mm2aX;uJI9nKGi3bXHuJGtOOTJiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1yLkC5Nlc2KM7:TR?= Ml;BV2FPT0WU
A204 cell MV3Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NHq5XnFKdmirYnn0bY9vKG:oIHj1cYFvKEF{MESgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlExODV{IN88US=> Mof3V2FPT0WU
CAL-51 cell MWrHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NXW0U5NpUW6qaXLpeIlwdiCxZjDoeY1idiCFQVytOVEh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0xNjFyN{C5JO69VQ>? MmXTV2FPT0WU
human A431 cell MULHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MoP3TY5pcWKrdHnvckBw\iCqdX3hckBCPDNzIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MD6xNVIyPiEQvF2= NFnMTVFUSU6JRWK=
NCI-H650 cell NXTFNnB2T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NGficGtKdmirYnn0bY9vKG:oIHj1cYFvKE6FST3IOlUxKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OC5zMUewPEDPxE1? M4fuZ3NCVkeHUh?=
A427 cell NVL0[JJiT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NFj6boFKdmirYnn0bY9vKG:oIHj1cYFvKEF2MkegZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlEyQTF6IN88US=> MWnTRW5ITVJ?
human 769-P cell Mn\SS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? M3TJOWlvcGmkaYTpc44hd2ZiaIXtZY4hPzZ7LWCgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlEzODh{IN88US=> Ml64V2FPT0WU
SW1710 cell NV;ZNXNzT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NWrr[YtZUW6qaXLpeIlwdiCxZjDoeY1idiCVV{G3NVAh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0xNjF|M{G2JO69VQ>? M3P1SnNCVkeHUh?=
human H4 cell NHzVO4xIem:5dHigbY5pcWKrdHnvckBie3OjeR?= Mnf2TY5pcWKrdHnvckBw\iCqdX3hckBJPCClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTBwMUO5OlMh|ryP MWnTRW5ITVJ?
HT-1080 cell MkfIS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NISzd5ZKdmirYnn0bY9vKG:oIHj1cYFvKEiWLUGwPFAh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0xNjF3OUiyJO69VQ>? M2Pmb3NCVkeHUh?=
human PANC-03-27 cell MmDWS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? M1nFNmlvcGmkaYTpc44hd2ZiaIXtZY4hWEGQQz2wN{0zPyClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTBwMU[wNkDPxE1? MXvTRW5ITVJ?
A375 cells MVrDfZRwfG:6aXPpeJkh[XO|YYm= NUjtXWI1PzJiaB?= M1v2S3RwgGmlaYT5JIFo[Wmwc4SgbJVu[W5iQUO3OUBk\WyuczDh[pRmeiB5MjDodpMh[nliY3XscEB1cXSncj3icJVmKGG|c3H5MEBKSzVyPUCuNVgh|ryP NEHwUJYyQTZ3NESwPC=>
human HOP-62 cell MoT6SpVv[3Srb36gZZN{[Xl? NFS3VmZKdmirYnn0bY9vKG:oIHj1cYFvKEiRUD22NkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVAvOThyN{Og{txO NYPOR5c2W0GQR1XS
human U031 cell MkXDS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MVjJcohq[mm2aX;uJI9nKGi3bXHuJHUxOzFiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1yLkG5Olk5KM7:TR?= NF3ofnZUSU6JRWK=
mouse BAF3 cells MmX0VJJwdGmoZYLheIlwdiCjc4PhfS=> NHfyWm9CdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JI1wfXOnIFLBSlMh[2WubIOgeJJidnOob4Lt[YQhf2m2aDDaUmYyQThvRlfGVlEh[2:wc4TyeYN1NCCLQ{WwQVAvOiEQvF2= M1;6PVIyQTN4NUSy
human G-402 cell NUG5clVIT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NEH6R2xKdmirYnn0bY9vKG:oIHj1cYFvKEdvNECyJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE4zODJ3MzFOwG0> NHTOTHZUSU6JRWK=
human G-361 cell MU\Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NVfNd3ZiUW6qaXLpeIlwdiCxZjDoeY1idiCJLUO2NUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVAvOjB6NUOg{txO MUjTRW5ITVJ?
NCI-H810 cell MlTCS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MV\Jcohq[mm2aX;uJI9nKGi3bXHuJG5EUS2KOEGwJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE4zOTB{NzFOwG0> NWKxdZFKW0GQR1XS
NCI-H2030 cell MVXHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MoDvTY5pcWKrdHnvckBw\iCqdX3hckBPS0lvSEKwN|Ah[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0xNjJ|MEC2JO69VQ>? NIX1U|JUSU6JRWK=
human HCT-116 cell NU\SdncxT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NHe4SYlKdmirYnn0bY9vKG:oIHj1cYFvKEiFVD2xNVYh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0xNjJ|NU[4JO69VQ>? MYfTRW5ITVJ?
human SNU-423 cell MmXrS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NYX2ZohVUW6qaXLpeIlwdiCxZjDoeY1idiCVTmWtOFI{KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OC5{M{[1O{DPxE1? NFjMfW5USU6JRWK=
human SCC-4 cell NX\SSoxVT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= M3vzV2lvcGmkaYTpc44hd2ZiaIXtZY4hW0OFLUSgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlI{QTZ5IN88US=> MXXTRW5ITVJ?
human SW48 cell Mn7TS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? Mom3TY5pcWKrdHnvckBw\iCqdX3hckBUXzR6IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MD6yOlY5KM7:TR?= MV\TRW5ITVJ?
human SF295 cell NFL2fYhIem:5dHigbY5pcWKrdHnvckBie3OjeR?= Mkf4TY5pcWKrdHnvckBw\iCqdX3hckBUTjJ7NTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUCuNlczPTdizszN M3PPd3NCVkeHUh?=
MDA-MB-231 cell NGXC[odIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MWLJcohq[mm2aX;uJI9nKGi3bXHuJG1FSS2PQj2yN|Eh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0xNjJ6MUCxJO69VQ>? NGHWSIhUSU6JRWK=
A172 cell NV3ZUo86T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MkHSTY5pcWKrdHnvckBw\iCqdX3hckBCOTd{IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MD6yPVE2KM7:TR?= MkG1V2FPT0WU
human BCPAP cell M1XoNWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M{TzdWlvcGmkaYTpc44hd2ZiaIXtZY4hSkOSQWCgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlI6QDd7IN88US=> M1\zOHNCVkeHUh?=
human COLO-792 cell MVvHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? M2rLTGlvcGmkaYTpc44hd2ZiaIXtZY4hS0:OTz23PVIh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0xNjJ7OUeyJO69VQ>? NVrxXGFDW0GQR1XS
human DU-145 cell M1LUO2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M4jUdWlvcGmkaYTpc44hd2ZiaIXtZY4hTFVvMUS1JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE4{OTh6OTFOwG0> NHrrdYpUSU6JRWK=
NCI-H2122 cell NWLIRoVZT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MUPJcohq[mm2aX;uJI9nKGi3bXHuJG5EUS2KMkGyNkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVAvOzJ{OEWg{txO NF;LO|JUSU6JRWK=
human SK-UT-1 cell MV7Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MUfJcohq[mm2aX;uJI9nKGi3bXHuJHNMNVWWLUGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlMzQTV{IN88US=> MVPTRW5ITVJ?
LXF-289 cell MVvHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MVLJcohq[mm2aX;uJI9nKGi3bXHuJGxZTi1{OEmgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlMzQTZ3IN88US=> Mo\LV2FPT0WU
human NCI-H1792 cell M4\GdWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M1O5SWlvcGmkaYTpc44hd2ZiaIXtZY4hVkOLLVixO|kzKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OC5|M{C5OkDPxE1? NVTqWFFEW0GQR1XS
MCF7 cell NV3ZO4U4T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MXzJcohq[mm2aX;uJI9nKGi3bXHuJG1ETjdiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1yLkOzNlc1KM7:TR?= NXfJb4JZW0GQR1XS
HCT-15 cell NH7DRnNIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NVvVWo1yUW6qaXLpeIlwdiCxZjDoeY1idiCKQ2StNVUh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0xNjN|NEOyJO69VQ>? M4P2TnNCVkeHUh?=
human NCI-H358 cell NEXR[IlIem:5dHigbY5pcWKrdHnvckBie3OjeR?= Mo\iTY5pcWKrdHnvckBw\iCqdX3hckBPS0lvSEO1PEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVAvOzN3NUGg{txO NFXibpFUSU6JRWK=
human HLE cell NV71S5g5T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NITmV4dKdmirYnn0bY9vKG:oIHj1cYFvKEiORTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUCuN|M4PTJizszN NGf3VWRUSU6JRWK=
human SW1088 cell NGq1fopIem:5dHigbY5pcWKrdHnvckBie3OjeR?= M4fxcGlvcGmkaYTpc44hd2ZiaIXtZY4hW1dzMEi4JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE4{Ozd7NzFOwG0> MX;TRW5ITVJ?
human K5 cell MVHHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MmTtTY5pcWKrdHnvckBw\iCqdX3hckBMPSClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTBwM{[xOFkh|ryP M4[1dHNCVkeHUh?=
human SR cell MVzHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NFvMRWpKdmirYnn0bY9vKG:oIHj1cYFvKFOUIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MD6zOlU4OSEQvF2= M1XKPHNCVkeHUh?=
human Calu-3 cell NWPR[28{T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NYS3Oop3UW6qaXLpeIlwdiCxZjDoeY1idiCFYXz1MVMh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0xNjN4OEK1JO69VQ>? NFvETZhUSU6JRWK=
human SK-MEL-30 cell MmDaS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MnjZTY5pcWKrdHnvckBw\iCqdX3hckBUUy2PRVytN|Ah[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0xNjN7OUGzJO69VQ>? MX7TRW5ITVJ?
human SW780 cell NFW0cnVIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MkXsTY5pcWKrdHnvckBw\iCqdX3hckBUXzd6MDDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUCuOFEyPDJizszN M2WyWnNCVkeHUh?=
NCI-H1563 cell M3zsS2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MlzGTY5pcWKrdHnvckBw\iCqdX3hckBPS0lvSEG1OlMh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0xNjRzNEi0JO69VQ>? M2rpe3NCVkeHUh?=
human MKN45 cell M2r4e2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NWHyVYlpUW6qaXLpeIlwdiCxZjDoeY1idiCPS160OUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVAvPDF7M{Gg{txO NYK1PIpOW0GQR1XS
MDA-MB-157 cell M3;YPGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NYDlTGZHUW6qaXLpeIlwdiCxZjDoeY1idiCPRFGtUWIuOTV5IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MD60NlAyPSEQvF2= NXfvdmpCW0GQR1XS
human NCI-H522 cell NIjISJlIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NYXHTZFWUW6qaXLpeIlwdiCxZjDoeY1idiCQQ1mtTFUzOiClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTBwNEKzJO69VQ>? MVPTRW5ITVJ?
human A2780 cell MYPHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NIfPfJFKdmirYnn0bY9vKG:oIHj1cYFvKEF{N{iwJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE41PzVyMzFOwG0> MmK4V2FPT0WU
human A498 cell NH\ve5NIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MnPJTY5pcWKrdHnvckBw\iCqdX3hckBCPDl6IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MD60O|Y6OyEQvF2= MWnTRW5ITVJ?
human BxPC-3 cell M2fzNWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MkDmTY5pcWKrdHnvckBw\iCqdX3hckBDgFCFLUOgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlQ6OzZ4IN88US=> Mn3xV2FPT0WU
human A2058 cell MYHHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NV\YNVB6UW6qaXLpeIlwdiCxZjDoeY1idiCDMkC1PEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVAvPTJ6NESg{txO M165fnNCVkeHUh?=
human PC-14 cell M2\Zd2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M{\JT2lvcGmkaYTpc44hd2ZiaIXtZY4hWENvMUSgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlU{QDV3IN88US=> NI\HTnRUSU6JRWK=
human KG-1 cell NVPSbmtCT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= M{jwVWlvcGmkaYTpc44hd2ZiaIXtZY4hU0dvMTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUCuOVU1OTlizszN M4rkfHNCVkeHUh?=
human A375 cell Mo[0S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? Mo\xTY5pcWKrdHnvckBw\iCqdX3hckBCOzd3IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MD61OlExOyEQvF2= NFXxfW1USU6JRWK=
human SW1783 cell MkjoS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MlX1TY5pcWKrdHnvckBw\iCqdX3hckBUXzF5OEOgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlc{OzdizszN MUjTRW5ITVJ?
human MKN1 cell NF60T4dIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MXjJcohq[mm2aX;uJI9nKGi3bXHuJG1MVjFiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1yLki4OFEzKM7:TR?= M1;IWXNCVkeHUh?=
NCI-H1650 cell M17qemdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MlzuTY5pcWKrdHnvckBw\iCqdX3hckBPS0lvSEG2OVAh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0xNjh6OUG256CB|ryP NHTqVJFUSU6JRWK=
human HT-1376 cell MoHZS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MVvJcohq[mm2aX;uJI9nKGi3bXHuJGhVNTF|N{[gZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlkzQTF6IN88US=> NGX1UFVUSU6JRWK=
SW872 cell M3rGbmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MlywTY5pcWKrdHnvckBw\iCqdX3hckBUXzh5MjDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUCuPVQ1PTlizszN MUDTRW5ITVJ?
human RT-112 cell M3u2VGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M3y4UWlvcGmkaYTpc44hd2ZiaIXtZY4hWlRvMUGyJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE46PzR6MzFOwG0> M3:yNnNCVkeHUh?=
human HT-29 cell M3nvVGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NUPwTZZtUW6qaXLpeIlwdiCxZjDoeY1idiCKVD2yPUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVAvQTd7OU[g{txO NUTZeVJKW0GQR1XS
human U-266 cell M2SySWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 Mn;QTY5pcWKrdHnvckBw\iCqdX3hckBWNTJ4NjDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUCuPVg{ODJizszN NV;zWnh5W0GQR1XS
human HEL cell MVXHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NIOzNnJKdmirYnn0bY9vKG:oIHj1cYFvKEiHTDDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUCuPVg2OTdizszN MnXXV2FPT0WU
human KU812 cell Mnv0S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NWf3flVbUW6qaXLpeIlwdiCxZjDoeY1idiCNVUixNkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVEvOTFzNkSg{txO M1rqe3NCVkeHUh?=

... Click to View More Cell Line Experimental Data

In vivo Midostaurin(pkc412) may suppress tumor growth by inhibiting tumor angiogenesis (via its effects on the VEGF receptor tyrosine kinases) in addition to directly inhibiting tumor cell proliferation (via its effects on PKCs). This anti-angiogenic action may contribute to the antimetastatic and broad antitumor activity displayed by midostaurin(pkc412), as well as the synergy with cytotoxic agents, including doxorubicin, cyclophosphamide, cisplatin and gemcitabine. When given orally, the maximally tolerated dose for midostaurin(pkc412) is >300 mg/kg. [1]

Protocol

Cell Research:[2]
+ Expand
  • Cell lines: A549, NCI-H520
  • Concentrations: ~1.0 μM
  • Incubation Time: 24-72 h
  • Method: Each well is added with 5 mM WST-1 and 0.2 mM 1-methoxy PMS and the absorbance at 450 nm is measured by a Microplate Reader.
    (Only for Reference)
Animal Research:[1]
+ Expand
  • Animal Models: Colo 205 colorectal tumors xenograft
  • Formulation: sterile water
  • Dosages: 50 mg/kg, 200 mg/kg, once daily
  • Administration: p.o.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 100 mg/mL (175.24 mM)
Ethanol 20 mg/mL warmed (35.04 mM)
Water Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
5% DMSO+45% PEG 300+ddH2O
For best results, use promptly after mixing.
4mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 570.64
Formula

C35H30N4O4

CAS No. 120685-11-2
Storage powder
in solvent
Synonyms CGP 41251

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT03836209 Not yet recruiting Acute Myeloid Leukemia PrECOG LLC.|Astellas Pharma Inc July 2019 Phase 2
NCT03836209 Not yet recruiting Acute Myeloid Leukemia PrECOG LLC.|Astellas Pharma Inc July 2019 Phase 2
NCT03760445 Not yet recruiting Leukemia Myeloid Acute Novartis Pharmaceuticals|Novartis February 28 2019 Phase 1|Phase 2
NCT03760445 Not yet recruiting Leukemia Myeloid Acute Novartis Pharmaceuticals|Novartis February 28 2019 Phase 1|Phase 2
NCT03591510 Not yet recruiting FLT3-mutated Acute Myeloid Leukemia Novartis Pharmaceuticals|Novartis December 28 2018 Phase 2
NCT03591510 Not yet recruiting FLT3-mutated Acute Myeloid Leukemia Novartis Pharmaceuticals|Novartis December 28 2018 Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

PKC Signaling Pathway Map

Related PKC Products0

Tags: buy Midostaurin (PKC412) | Midostaurin (PKC412) supplier | purchase Midostaurin (PKC412) | Midostaurin (PKC412) cost | Midostaurin (PKC412) manufacturer | order Midostaurin (PKC412) | Midostaurin (PKC412) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID